LY3009120 is primarily utilized in research settings as a pan-RAF inhibitor, targeting the RAF kinase family, which plays a critical role in the MAPK/ERK signaling pathway. This pathway is often dysregulated in various cancers, making LY3009120 a valuable tool for studying tumor growth and proliferation. It is particularly effective in inhibiting both monomeric and dimeric forms of RAF kinases, which helps in understanding the mechanisms of resistance to other RAF inhibitors. Researchers use LY3009120 to explore its potential in treating cancers with BRAF mutations, such as melanoma, colorectal cancer, and thyroid cancer. Additionally, it is employed in preclinical studies to assess its efficacy and safety profile, paving the way for potential therapeutic applications in oncology.